SHORT-TERM EFFECTS OF TESTOSTERONE REPLACEMENT THERAPY ON RISK PREDICTORS FOR ARTERIOSCLEROSIS AMONG MEN WITH LATE-ONSET HYPOGONADISM: A CASE–CONTROL STUDY

Background and objective This study assessed the short-term effects of testosterone replacement therapy (TRT) on some risk predic-tors for arteriosclerosis among men with late-onset hypogonadism (LOH).Materials and methods A total of 25 patients with LOH who received TRT for 6 months and 21 patients without TRT were enrolled in the present study. Information regarding the following parameters were collected: Aging Males’ Symptoms scale, Sexual Health Inventory for Men (SHIM), International Prostatic Symptom Score, waist circumfer-ence, and some laboratory data, including fasting blood sugar, hemoglobin A1c (HbA1c), low-density lipo-protein cholesterol, triglycerides, high-density lipoprotein cholesterol, high-sensitivity C-reactive protein (hs-CRP) values, and arteriosclerosis index (AI), at baseline and after 6 months. Patients in the TRT group had received intramuscular injections of testosterone enanthate (250 mg) every month for 6 months while those in the control group received no testosterone treatment during this trial.Results No significant differences were observed in any baseline patient characteristics between both groups. After 6 months, the TRT group exhibited significant improvements in SHIM scores (from 10.1 to 13.1; p = 0.00563), hs-CRP values (from 0.157 to 0.103 mg/dL; p = 0.00753), and the AI (from 2.10 to 1.95 mg/dL; p = 0.0429), with a significant decrease in AMS scale (from 44.3 to 41.8; p = 0.0388). The control group dis-played no significant changes in all parameters. No patient in the TRT group had additional interventions or medications worsening their urinary symptoms.Conclusions TRT for 6 months among men with LOH contributed to significant improvements in three predictive fac-tors for arteriosclerosis. Further studies including long-term TRT are expected to demonstrate the preven-tive effects of testosterone for arteriosclerosis among Japanese men with LOH syndrome.

[1]  G. Doros,et al.  Long-term treatment with testosterone undecanoate injections in men with hypogonadism alleviates erectile dysfunction and reduces risk of major adverse cardiovascular events, prostate cancer, and mortality , 2020, The aging male : the official journal of the International Society for the Study of the Aging Male.

[2]  Hun‐Sung Kim,et al.  Effect of visit-to-visit LDL-, HDL-, and non-HDL-cholesterol variability on mortality and cardiovascular outcomes after percutaneous coronary intervention. , 2018, Atherosclerosis.

[3]  A. Dobs,et al.  Analysis of cardiovascular risk factors associated with serum testosterone levels according to the US 2011–2012 National Health and Nutrition Examination Survey , 2018, The aging male : the official journal of the International Society for the Study of the Aging Male.

[4]  M Namiki,et al.  Effects of testosterone replacement therapy on metabolic syndrome among Japanese hypogonadal men: A subanalysis of a prospective randomised controlled trial (EARTH study) , 2018, Andrologia.

[5]  Y. Wang,et al.  Testosterone replacement therapy improves health‐related quality of life for patients with late‐onset hypogonadism: a meta‐analysis of randomized controlled trials , 2017, Andrologia.

[6]  Y. Takagi,et al.  Role of the Low-Density Lipoprotein-Cholesterol/High-Density Lipoprotein-Cholesterol Ratio in Predicting Serial Changes in the Lipid Component of Coronary Plaque. , 2017, Circulation journal : official journal of the Japanese Circulation Society.

[7]  Y. Kitagawa,et al.  The correlation between highly sensitive C-reactive protein levels and erectile function among men with late-onset hypogonadism , 2016, The aging male : the official journal of the International Society for the Study of the Aging Male.

[8]  E. Rhoden,et al.  Total testosterone levels are correlated to metabolic syndrome components , 2016, The aging male : the official journal of the International Society for the Study of the Aging Male.

[9]  G. Doros,et al.  Effects of intermission and resumption of long‐term testosterone replacement therapy on body weight and metabolic parameters in hypogonadal in middle‐aged and elderly men , 2016, Clinical endocrinology.

[10]  S. Hisasue.  Contemporary perspective and management of testosterone deficiency: Modifiable factors and variable management , 2015, International journal of urology : official journal of the Japanese Urological Association.

[11]  S. Arver,et al.  Recommendations on the diagnosis, treatment and monitoring of hypogonadism in men , 2015, The aging male : the official journal of the International Society for the Study of the Aging Male.

[12]  V. Mesch,et al.  Association between testosterone levels and the metabolic syndrome in adult men , 2014, The aging male : the official journal of the International Society for the Study of the Aging Male.

[13]  M. Rutter,et al.  Late-onset hypogonadism and mortality in aging men. , 2014, The Journal of clinical endocrinology and metabolism.

[14]  A. Traish,et al.  Long-term testosterone therapy in hypogonadal men ameliorates elements of the metabolic syndrome: an observational, long-term registry study , 2013, International journal of clinical practice.

[15]  N. Smith,et al.  Testosterone treatment and mortality in men with low testosterone levels. , 2012, The Journal of clinical endocrinology and metabolism.

[16]  C. Vlachopoulos,et al.  Prediction of Cardiovascular Events and All-Cause Mortality With Erectile Dysfunction: A Systematic Review and Meta-Analysis of Cohort Studies , 2012, Circulation. Cardiovascular quality and outcomes.

[17]  C. Fraile,et al.  Testosterone undecanoate improves erectile dysfunction in hypogonadal men with the metabolic syndrome refractory to treatment with phosphodiesterase type 5 inhibitors alone , 2011, Andrologia.

[18]  F. Akhras,et al.  Cardiovascular diseases and erectile dysfunction: the two faces of the coin of androgen deficiency , 2011, Andrologia.

[19]  S. Kaplan,et al.  Elevated high sensitivity C-reactive protein levels in aging men with low testosterone , 2010, The aging male : the official journal of the International Society for the Study of the Aging Male.

[20]  A. Traish,et al.  Androgen deficiency and atherosclerosis: The lipid link. , 2009, Vascular pharmacology.

[21]  C. Gazzaruso,et al.  Erectile dysfunction as a predictor of cardiovascular events and death in diabetic patients with angiographically proven asymptomatic coronary artery disease: a potential protective role for statins and 5-phosphodiesterase inhibitors. , 2008, Journal of the American College of Cardiology.

[22]  H. Akaza,et al.  Clinical Practice Manual for Late‐onset Hypogonadism Syndrome , 2008, International journal of urology : official journal of the Japanese Urological Association.

[23]  M. Pfeffer,et al.  Prognostic Significance of the Centers for Disease Control/American Heart Association High-Sensitivity C-Reactive Protein Cut Points for Cardiovascular and Other Outcomes in Patients With Stable Coronary Artery Disease , 2007, Circulation.

[24]  F. Montorsi,et al.  Association between erectile dysfunction and coronary artery disease. Role of coronary clinical presentation and extent of coronary vessels involvement: the COBRA trial. , 2006, European heart journal.

[25]  P. Macfarlane,et al.  Plasma Lipoproteins and Apolipoproteins as Predictors of Cardiovascular Risk and Treatment Benefit in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER) , 2005, Circulation.

[26]  D. Mertz.  ["Atherosclerosis-index" (LDL/HDL): risk indicator in lipid metabolism disorders]. , 1980, Medizinische Klinik.

[27]  Erasmus Mc,et al.  Erectile dysfunction prospectively associated with cardiovascular disease in the Dutch general population: results from the Krimpen Study , 2008, International Journal of Impotence Research.